Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from BioMarin Pharmaceutical ( (BMRN) ).
On August 5, 2025, BioMarin Pharmaceutical announced the resignation of Erin Burkhart, their Group Vice President and Chief Accounting Officer, effective September 2, 2025. The company will search for her successor, and in the interim, Brian Mueller, the Executive Vice President and Chief Financial Officer, will assume her responsibilities without additional compensation.
The most recent analyst rating on (BMRN) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.
Spark’s Take on BMRN Stock
According to Spark, TipRanks’ AI Analyst, BMRN is a Outperform.
BioMarin Pharmaceutical’s overall stock score reflects strong financial performance and positive strategic developments, particularly in revenue growth and product expansion. The earnings call provided a positive outlook, although operational challenges and technical indicators suggest caution. The company’s valuation is reasonable, supporting a solid investment case.
To see Spark’s full report on BMRN stock, click here.
More about BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. operates in the biotechnology industry, focusing on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions.
Average Trading Volume: 2,338,557
Technical Sentiment Signal: Sell
Current Market Cap: $11.01B
For detailed information about BMRN stock, go to TipRanks’ Stock Analysis page.